AstraZeneca, Roche, Teva Reported As Suitors For South Korea's Biosimilar Front-runner Celltrion
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca, Roche and Teva Pharmaceutical Industries are reported to be among suitors showing an interest in South Korea's biosimilar leader Celltrion.